Hikma Pharmaceuticals PLC (LON: HIK)
London
· Delayed Price · Currency is GBP · Price in GBX1,881.00
+14.00 (0.75%)
Jul 22, 2024, 1:35 PM GMT
Hikma Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year Ending | TTM | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,875 | 2,875 | 2,517 | 2,553 | 2,341 | 2,207 | Upgrade
|
| Revenue Growth (YoY) | 14.22% | 14.22% | -1.41% | 9.06% | 6.07% | 6.62% | Upgrade
|
| Cost of Revenue | 1,468 | 1,468 | 1,252 | 1,252 | 1,128 | 1,108 | Upgrade
|
| Gross Profit | 1,407 | 1,407 | 1,265 | 1,301 | 1,213 | 1,099 | Upgrade
|
| Selling, General & Admin | 632 | 632 | 601 | 561 | 506 | 487 | Upgrade
|
| Research & Development | 149 | 149 | 144 | 143 | 137 | 126 | Upgrade
|
| Other Operating Expenses | 7 | 7 | 22 | 36 | 30 | - | Upgrade
|
| Operating Expenses | 788 | 788 | 767 | 740 | 673 | 613 | Upgrade
|
| Operating Income | 619 | 619 | 498 | 561 | 540 | 486 | Upgrade
|
| Interest Expense | -73 | -73 | -59 | -43 | -41 | -36 | Upgrade
|
| Interest & Investment Income | 7 | 7 | 3 | 1 | 7 | 6 | Upgrade
|
| Net Interest Expenses | -66 | -66 | -56 | -42 | -34 | -30 | Upgrade
|
| Income (Loss) On Equity Investments | - | - | - | 1 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -3 | -3 | -7 | - | - | -3 | Upgrade
|
| Other Non Operating Income (Expenses) | -14 | -14 | -11 | -13 | -11 | -16 | Upgrade
|
| EBT Excluding Unusual Items | 536 | 536 | 424 | 507 | 495 | 437 | Upgrade
|
| Merger & Restructuring Charges | - | - | -41 | - | -3 | -7 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 12 | -1 | -2 | -3 | Upgrade
|
| Gain (Loss) on Sale of Investments | 2 | 2 | -2 | - | 1 | -2 | Upgrade
|
| Asset Writedown | -85 | -85 | -182 | 22 | 33 | 18 | Upgrade
|
| Other Unusual Items | -43 | -43 | 22 | 16 | 23 | 16 | Upgrade
|
| Pretax Income | 281 | 281 | 233 | 544 | 558 | 491 | Upgrade
|
| Income Tax Expense | 89 | 89 | 42 | 124 | 128 | 4 | Upgrade
|
| Earnings From Continuing Operations | 192 | 192 | 191 | 420 | 430 | 487 | Upgrade
|
| Minority Interest in Earnings | -2 | -2 | -3 | 1 | 1 | -1 | Upgrade
|
| Net Income | 190 | 190 | 188 | 421 | 431 | 486 | Upgrade
|
| Net Income to Common | 190 | 190 | 188 | 421 | 431 | 486 | Upgrade
|
| Net Income Growth | 1.06% | 1.06% | -55.34% | -2.32% | -11.32% | 72.34% | Upgrade
|
| Shares Outstanding (Basic) | 221 | 221 | 224 | 231 | 236 | 242 | Upgrade
|
| Shares Outstanding (Diluted) | 222 | 222 | 225 | 233 | 238 | 243 | Upgrade
|
| Shares Change (YoY) | -1.13% | -1.13% | -3.47% | -2.10% | -2.06% | 0.41% | Upgrade
|
| EPS (Basic) | 0.86 | 0.86 | 0.84 | 1.82 | 1.83 | 2.01 | Upgrade
|
| EPS (Diluted) | 0.85 | 0.85 | 0.84 | 1.81 | 1.81 | 2.00 | Upgrade
|
| EPS Growth | 1.19% | 1.19% | -53.51% | -0.22% | -9.45% | 71.67% | Upgrade
|
| Free Cash Flow | 439 | 439 | 392 | 493 | 292 | 353 | Upgrade
|
| Free Cash Flow Per Share | 1.97 | 1.97 | 1.74 | 2.12 | 1.23 | 1.45 | Upgrade
|
| Dividend Per Share | 0.720 | 0.720 | 0.560 | 0.540 | 0.500 | 0.440 | Upgrade
|
| Dividend Growth | 28.57% | 28.57% | 3.70% | 8.00% | 13.64% | 15.79% | Upgrade
|
| Gross Margin | 48.94% | 48.94% | 50.26% | 50.96% | 51.82% | 49.80% | Upgrade
|
| Operating Margin | 21.53% | 21.53% | 19.79% | 21.97% | 23.07% | 22.02% | Upgrade
|
| Profit Margin | 6.61% | 6.61% | 7.47% | 16.49% | 18.41% | 22.02% | Upgrade
|
| Free Cash Flow Margin | 15.27% | 15.27% | 15.57% | 19.31% | 12.47% | 15.99% | Upgrade
|
| EBITDA | 791 | 791 | 670 | 718 | 654 | 584 | Upgrade
|
| EBITDA Margin | 27.51% | 27.51% | 26.62% | 28.12% | 27.94% | 26.46% | Upgrade
|
| D&A For EBITDA | 172 | 172 | 172 | 157 | 114 | 98 | Upgrade
|
| EBIT | 619 | 619 | 498 | 561 | 540 | 486 | Upgrade
|
| EBIT Margin | 21.53% | 21.53% | 19.79% | 21.97% | 23.07% | 22.02% | Upgrade
|
| Effective Tax Rate | 31.67% | 31.67% | 18.03% | 22.79% | 22.94% | 0.81% | Upgrade
|
Source: S&P Capital IQ. Standard template.